Pirenzepine-d8

Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.

Product Specifications

CAS Number

[1189944-02-2]

Product Name Alternative

LS 519-d8 (free base) ; Pirenzepin-d8; Gastrozepin-d8

UNSPSC

12352005

Target

Isotope-Labeled Compounds; mAChR

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Inflammation/Immunology; Neurological Disease

Solubility

10 mM in DMSO

Smiles

O=C1NC2=CC=CN=C2N(C(CN3C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C3([2H])[2H])=O)C4=CC=CC=C14

Molecular Formula

C19H13D8N5O2

Molecular Weight

359.45

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Del Tacca M, et al. A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties. Minerva Dietol Gastroenterol. 1989 Jul-Sep;35 (3) :175-89.|[3]Ojewole JA, et al. Effects of pirenzepine (Gastrozepin) on skeletal muscle contractility. Methods Find Exp Clin Pharmacol. 1983 Nov;5 (9) :619-23.|[4]Caulfield MP, et al. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passiveavoidance learning in the mouse. J Pharm Pharmacol. 1983 Feb;35 (2) :131-2.|[5]Hirschowitz BI, et al. Effects of pirenzepine and atropine on vagal and cholinergic gastric secretion and gastrin release and on heart rate in the dog. J Pharmacol Exp Ther. 1983 May;225 (2) :263-8.